---
title: "Evaxion Biotech: Strong R&D progress and financial discipline support a cash runway into H2 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296546698.md"
description: "Q2 2026 saw strong R&D progress, with new clinical data validating the AI-Immunology platform and pipeline expansion in oncology and infectious diseases. Financial discipline was maintained, with a net loss of $3.7 million and a cash runway into the second half of 2027.Original document: Evaxion Biotech Slides Release — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-20T23:48:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296546698.md)
  - [en](https://longbridge.com/en/news/296546698.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296546698.md)
generator: "portal-rs"
---

# Evaxion Biotech: Strong R&D progress and financial discipline support a cash runway into H2 2027

Q2 2026 saw strong R&D progress, with new clinical data validating the AI-Immunology platform and pipeline expansion in oncology and infectious diseases. Financial discipline was maintained, with a net loss of $3.7 million and a cash runway into the second half of 2027.

Original document: Evaxion Biotech Slides Release — Aug. 20 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md)

## Related News & Research

- [New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 | EVAX Stock News](https://longbridge.com/en/news/304667725.md)
- [Evaxion reports EVX-01 induces strong immune responses in phase 2 melanoma trial](https://longbridge.com/en/news/304666419.md)
- [Evaxion to Present Phase 2 Biomarker Data for Cancer Vaccine EVX-01 at SITC 2026](https://longbridge.com/en/news/304126126.md)
- [Evaxion reports new data supporting EVX-04 vaccine for acute myeloid leukemia](https://longbridge.com/en/news/304289974.md)
- [CoreWeave CEO Says He Has Buyers for All Its Future AI Capacity but Won’t Sell Yet](https://longbridge.com/en/news/305196611.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**